Calibrated Signal — Hard science. Honest signal.

What Twenty Years of “Borderline” Blood Pressure Actually Costs You

By Nick Hanson29 min read
A blood pressure cuff connected by tubing to an hourglass, the sand mid-fall in a warm rust amber tone, visualizing blood pressure as a dose accumulating over time

Blood pressure isn’t a moment. It’s a dose, accumulating year after year.

Imagine a 35-year-old whose blood pressure reads 132/85 at their annual physical. Their physician glances at the number and calls it “borderline.” Maybe a vague suggestion to cut back on salt, lose a few pounds, recheck in a year. Nothing in the conversation feels alarming.

Now imagine that same person, twenty years later, being wheeled into a cath lab with a critical occlusion in their right coronary artery. The plaque causing the obstruction didn’t show up overnight. It accumulated, every year, while their blood pressure was “borderline.” The number at 35 didn’t move the conversation. The number at 45 didn’t either. The number at 55 finally did, but by then it was a procedure rather than a prevention. Unfortunately this was me. As I have mentioned in previous posts, I didn’t visit the doctor often when I was in my 20s and 30s. I was healthy and rarely if ever got sick. I honestly didn’t even go to yearly physicals most years. However, I do know that my blood pressure was never that “perfect” 120/80 or below. It also was never horrible, even though by today’s guidelines I had hypertension.

The numbers behind this aren’t soft. In the largest meta-analysis ever assembled on the topic, pooling individual data from over one million adults across sixty-one cohort studies, the relationship between blood pressure and cardiovascular mortality was continuous and linear all the way down to a systolic of 115 mmHg and a diastolic of 75 mmHg.2 From that point upward, every additional 20 mmHg systolic or 10 mmHg diastolic was associated with roughly a doubling in the risk of death from heart disease and stroke. The relationship had no inflection point. No threshold below which it stopped mattering. The artery was logging the damage at every reading, every year, regardless of whether the doctor called the number “borderline” or “fine.”

The problem isn’t that 132/85 is a medical emergency. It almost never is. People show up to the emergency department every day with a chief complaint of being worried about high blood pressure. But the honest truth is that the medical system typically doesn’t look at blood pressure as an emergency until it gets up around 180/120. The damage starts long before those numbers. The other problem is that the standard cardiology and primary care visit workflow measures blood pressure as a snapshot, treats anything short of stage 2 hypertension as discretionary, and acts as if the years between snapshots don’t count. They do. And the cleanest evidence on this question all points the same way: Mendelian dose-response curves on lifelong exposure, a million-person meta-analysis of cardiovascular cohorts, decades of longitudinal cohort data on cumulative pressure load, and a marquee randomized trial that stopped early because the benefit was unmistakable. All of it says the same thing: what’s happening between your readings is doing most of the work.

Last week I walked through the cumulative math of borderline LDL and what twenty years of mildly elevated cholesterol actually does to an artery wall. This week I want to put borderline blood pressure through the same kind of treatment. The construct is identical. The numbers are different. The arithmetic is the chapter nobody walked through with me.

Because for most of my adult life, from somewhere in my early thirties through the day I got carted into the cath lab, my blood pressure averaged something like 132 over 85. Sometimes a little higher on the diastolic side, occasionally upper eighties. Not dramatic. Not the kind of number that automatically gets you a prescription. Just, as I wrote a few weeks ago when I named the cracks I’d dismissed, “not optimal.” I knew what optimal looked like. I had run a hundred blood pressures a shift in the ER. I wrote it off as white coat effect, or training stress, or just close enough. It was always “close enough.”

Twenty years of close enough is not a holding pattern. It’s an unfolding cost. And that cost is the math I want to walk through here, because I should have read it myself fifteen years ago.

What “borderline” actually means in current practice

For decades, primary-care medicine treated 140/90 as the line. Below the line, fine. Above the line, hypertension. That worked, more or less, in the era when the ten-year horizon was the only horizon. It does not work anymore.

In August 2025, the American College of Cardiology and the American Heart Association, together with eleven other professional societies, published the most consequential update to the U.S. blood pressure guideline since 2017.3 Two changes matter for anyone reading this with a systolic in the 130s.

The first is that “borderline” is no longer a clinical category. Anything 130/80 or above is now formally classified as Stage 1 hypertension. Not “elevated.” Not “borderline.” Not “prehypertension.” Stage 1. The same word the framework used to reserve for numbers that triggered a prescription. The threshold didn’t move because anyone changed their mind about biology; it moved because the cumulative-exposure evidence finally got too loud to ignore.

The second change is more clinically active. The 2025 guideline replaces the old Pooled Cohort risk equation with a new calculator called PREVENT, and it tightens the medication trigger for adults whose 10-year predicted risk is below 7.5%. If your average blood pressure is 130/80 or higher and a three-to-six-month trial of lifestyle modification doesn’t bring it under 130/80, the recommendation is now to start pharmacotherapy. The ACC’s own commentary acknowledges that this will lead to more younger patients getting prescribed antihypertensive therapy than before, because the cumulative exposure starts earlier in the life course than the old ten-year score was ever designed to see.

That, in plain terms, is the framework moving toward the math. The thirty-five-year-old at 132/85 isn’t a soft call anymore. They’re a stage-1 hypertensive on a twenty-year clock.

The advice that’s supposed to bridge the gap

The standard playbook for stage-1 hypertension still leads with lifestyle, and it should. The right answer for someone at 132/85 is rarely “start medication tomorrow.” The lifestyle prescription has real evidence behind it. Sodium restriction, alcohol moderation, weight loss when applicable, physical activity, the DASH-style eating pattern, treatment of obstructive sleep apnea when present. Each of these can move a borderline number measurably.

But the size of the move is where the framework quietly underperforms the math. The best dietary trials in well-controlled settings produce systolic drops on the order of 5 to 8 mmHg, sometimes more in highly motivated participants. Real-world adherence over years cuts those numbers further. Even a sustained 5 mmHg reduction is clinically meaningful at the population level. It is also not enough, on its own, to close a 15-to-20 mmHg gap on a continuous dose-response curve that extends down to 115 systolic. The gap that needs to close is bigger than the lifestyle prescription, as typically delivered, actually delivers.

This isn’t an argument against lifestyle. It’s an argument for honesty about what lifestyle alone does and doesn’t do for someone whose true average is in the low 130s. “We’ll watch it” only works if someone is actually watching. And for that to happen, the patient and the clinician have to be looking at the same thing: not the snapshot, but the trajectory.

Why we measure cigarettes in years and blood pressure in moments

Consider how we talk about a different kind of cumulative exposure. A pack of cigarettes a day for twenty years is twenty pack-years. No physician looks at twenty pack-years and shrugs because the patient happens not to be smoking on the morning of the appointment. The cumulative number is the diagnosis. Lung cancer risk, COPD risk, even smoking-attributable cardiovascular risk all scale with pack-years, not with the question of whether the patient inhaled in the parking lot before they walked in.

Pack-years sit inside the medical vocabulary because the arithmetic is what predicts outcome. It’s a continuous chemical insult to lung tissue over time, added up across years. The unit was invented because the moment was misleading and the running total was honest.

Blood pressure works the same way at the cellular level, with one important difference we’ll get to in a second. The artery doesn’t experience a number, it experiences a force, every beat, every minute, every year. The endothelial cells lining the inside of the vessel wall are being mechanically stressed continuously. The amount of damage they accumulate is a function of pressure times time, not pressure at one office visit. The screening framework just hasn’t absorbed the arithmetic the way it did for smoking.

Here’s the important difference, because the analogy isn’t clean. Cigarettes have a defensible zero. No cigarettes, no exposure, no plausible harm. Blood pressure does not work that way. Pressure isn’t bad; it’s necessary. The artery is built for a load, and the heart spends every beat producing that load to perfuse the brain, the kidneys, and the coronary tree itself. Drop the pressure low enough and the system fails the other way: syncope, ischemia, organ injury, death. I see the dangers of low blood pressure on a regular basis in the emergency department. The relationship between blood pressure and harm is J-shaped, not a straight line down to zero. The right metric, then, isn’t the running total of pressure across a lifetime. That would mean a dead person scores zero, which is the wrong direction of correctness. The right metric is excess blood-pressure years: the running total of pressure above a sensible reference baseline, accumulated across the years you spend above it.

Take 120/80 as the reference, since that’s the threshold most people associate with “normal” and the line above which the 2025 AHA/ACC guideline starts categorizing blood pressure as elevated or hypertensive. Honest caveat: the cleanest evidentiary floor in the Lewington data sits closer to 115/75; below that point the dose-response simply runs out of cohort data, not because going lower is dangerous but because we don’t have the studies to say otherwise. Going below ninety systolic in a typical adult is where you start inviting the J-curve’s other side. The exact baseline you pick changes the absolute size of the numbers in the next section but not the directional point.

Borderline blood pressure deserves the same mental model as pack-years, just with the floor moved up from zero to a sensible reference. Call it blood-pressure years, or mmHg-years, or just vessel wall exposure above baseline. The unit doesn’t matter. What matters is that the framework starts taking the running total seriously, the way it already does for cigarettes.

What cumulative blood pressure exposure actually measures

Cumulative excess blood pressure exposure is the area between your actual systolic curve and the 120 reference line, plotted against age and added up across the years you spend above it. Someone whose systolic averages 120 mmHg from age 20 to 65 accumulates zero excess mmHg-years. The artery is doing exactly the work it was built for. Someone who averages 134 mmHg across the same forty-five years accumulates 14 × 45 = 630 excess mmHg-years. That is the total “above baseline” load their artery has been absorbing every day for forty-five years.

That number doesn’t look enormous in isolation, but it represents an extra fourteen millimeters of mercury of force pushing on the inside of your arteries, continuously, for forty-five years. Every endothelial cell in your coronary tree, in your renal arteries, in your cerebral vessels, has been doing its job under a slightly heavier load every minute of every day. The cumulative cellular consequence of that load is what the snapshot model can’t see.

Two flat horizontal lines plotted across ages 20 to 65 — one at 116 mmHg systolic, one at 134 mmHg systolic — with the warm amber area between them labeled "+18 mmHg × 45 years = 810 mmHg-YEARS of extra wall stress"

Illustrative arithmetic across forty-five years. Two trajectories: one near Lewington’s evidence floor at 116, one in Stage 1 hypertension at 134. The amber band is the eighteen-mmHg-per-year average gap, accumulated. Whether you compare against the AHA/ACC reference of 120 or Lewington’s floor of 115, the directional point is the same: the higher trajectory carries hundreds of excess mmHg-years the lower one does not.

This isn’t a thought experiment. The major cardiovascular cohort studies have begun computing exposure metrics like this directly, adding up each individual’s blood-pressure trajectory across decades and then asking whether the running total predicts future events better than any single measurement. The answer, consistently, is yes. The Lifetime Risk Pooling Project, which combined data from five racially diverse U.S. cohorts followed into middle age, found that ten years of higher cumulative systolic exposure predicted both higher cardiovascular event rates and earlier age at first event, after adjusting for whatever the BP happened to be at the moment of measurement.6 The CARDIA cohort, which followed young adults from their late teens into their fifties, found cumulative blood-pressure exposure during young adulthood to be a strong predictor of heart failure, coronary disease, and stroke decades later, with hazard ratios that rose steadily with accumulated exposure.5 The unit may not yet be on your lab report. The biology has been computing it the whole time.

SPRINT: what happens when you actually pull the trigger

If cumulative exposure is the construct, the question that follows is whether actually lowering it earlier produces fewer events. That is what SPRINT was designed to answer, and the answer was decisive enough that the trial was stopped early on the recommendation of its safety board.1

SPRINT enrolled 9,361 adults aged 50 and older with a systolic blood pressure of 130 mmHg or higher and at least one additional cardiovascular risk factor, excluding patients with diabetes and prior stroke. The randomization was simple. One group was treated to a target systolic below 140 mmHg, the conventional goal at the time. The other group was treated to a target below 120 mmHg, the more intensive goal. At one year, the standard-treatment group averaged a systolic of 136.2 mmHg. The intensive-treatment group averaged 121.4 mmHg. A roughly 15-mmHg separation between arms, sustained.

The primary outcome, a composite of myocardial infarction, acute coronary syndrome, stroke, heart-failure hospitalization, and cardiovascular death, occurred in 1.65% per year of the intensive group and 2.19% per year of the standard group. The hazard ratio was 0.75. A 25% relative reduction, p < 0.001, with a 95% confidence interval (0.64 to 0.89) that did not come close to crossing one. All-cause mortality showed a hazard ratio of 0.73, a 27% relative reduction in death from any cause (95% CI 0.60 to 0.90, p = 0.003). The number needed to treat to prevent one primary outcome event was 61. To prevent one death, 90.

Those are large effect sizes for a cardiovascular trial. They are the reason the data and safety monitoring board recommended terminating the trial early. The benefit of pursuing a lower target was unmistakable in a high-risk middle-aged population, and continuing to randomize patients to a target that was now demonstrably inferior was no longer ethical.

A few caveats deserve to be on the record, because they shape how to apply SPRINT to a younger reader of this newsletter. The blood pressure measurements in SPRINT were taken using an automated office device after five minutes of seated rest, alone in the room. That technique typically reads several millimeters lower than the way blood pressure is measured in a typical primary-care office, where the cuff goes on shortly after the patient walks in, often mid-conversation. The practical consequence is that a SPRINT target of “below 120” corresponds to something more like “low 130s” in casually measured office settings, which is the same range we are talking about for the borderline patient. SPRINT also excluded patients with diabetes and prior stroke, two large groups for whom the answer may differ in nuance though not in direction. And serious adverse events such as syncope and acute kidney injury occurred more frequently in the intensive group, which is part of why the conversation about treatment intensity always belongs in the clinical encounter, not in a blog post.

But the trial’s central finding survives all of those caveats intact. Lowering pressure earlier and more aggressively, in a high-cardiovascular-risk middle-aged population, reduced events by a fourth and death by more than a fourth. That is what cumulative exposure looks like when you bend the curve. It is the cleanest evidence the field has that the running total is not just a descriptive metric but a modifiable one.

The million-adult dose-response

If SPRINT is the trial, Lewington 2002 is the field map. Published in The Lancet, the study pooled prospective individual-participant data from sixty-one cohort studies, totaling more than one million adults and around twelve million person-years of follow-up.2 It is the largest assembled analysis ever conducted on the relationship between blood pressure and vascular mortality, and remains the most widely cited estimate of dose-response in the field.

The finding is the one that should sit at the center of every conversation about a “borderline” reading. Across the systolic range of roughly 115 mmHg to 185 mmHg, in adults aged 40 to 69, each 20 mmHg increase in systolic pressure (or 10 mmHg diastolic) was associated with approximately a doubling of mortality from both ischemic heart disease and stroke. The relationship was continuous and steadily rising all the way down. There was no inflection point at 140. There was no inflection point at 130. There was, in fact, no observable threshold above 115/75 below which the relationship flattened.

This is what people miss when they hear “borderline.” They picture a soft category between “fine” and “high.” The Lewington data don’t show a soft category. They show a continuous dose-response in which the difference between 116 and 136 systolic, sustained over decades, is the same shape of risk relationship as the difference between 156 and 176, sustained over decades. The artery doesn’t know the difference between “borderline” and “moderate hypertension” any more than the lung knows the difference between “social smoker” and “pack-a-day.” It just adds up the exposure.

CARDIA: real-time confirmation in young arteries

Lewington gives us the dose-response across the broad adult population. CARDIA, the Coronary Artery Risk Development in Young Adults study, anchors the same finding in a younger cohort with continuous longitudinal data. CARDIA enrolled adults aged 18 to 30 in 1985 and 1986 and has followed them with serial assessments for nearly forty years.

When CARDIA investigators applied cumulative-exposure methods to the BP data, computing each participant’s area under the systolic curve from young adulthood forward and tracking cardiovascular events into midlife, the relationship that emerged paralleled what Lewington had described across an older population.5 Higher cumulative exposure in young adulthood was associated with later heart failure, coronary heart disease, stroke, and overall cardiovascular events. The hazard ratios moved steadily with exposure, and crucially, the relationship held even after adjusting for whatever the BP happened to be at the time of the event.

In other words: if you took two CARDIA participants who arrived at midlife with the same current blood pressure, the one whose accumulated exposure was higher carried the higher risk. The running total mattered after controlling for the snapshot. That is exactly what the cigarette-pack-years framework predicts. It is exactly what the snapshot framework cannot account for.

What this means for a 35-year-old at 132/85

Let me run the same math three ways for a thirty-five-year-old whose systolic has averaged around 134 mmHg since their early twenties, using 120 mmHg as the reference baseline and computing excess mmHg-years above it. Same structural exercise I walked through for cumulative LDL in last week’s chapter.

Two coronary artery cross-sections side-by-side, both lumens fully open; the left labeled "20 YEARS AT 116/72" shows a smooth healthy endothelium, the right labeled "20 YEARS AT 134/86" shows visibly thickened wall and three faint warm amber lipid streaks within the wall — early subclinical change without obstruction

Both arteries are fully patent. The difference between them is what the patient can’t feel and the snapshot can’t see.

Case A. A 35-year-old whose systolic has averaged 134 mmHg since age 20, fifteen years of cumulative exposure. Excess above the 120 reference: 14 mmHg. By age 35 they’ve accumulated 15 × 14 = 210 excess mmHg-years. If nothing changes, by age 45 they will have added another 140, reaching 350 excess mmHg-years. By age 65, 630 excess mmHg-years.

Case B. Same patient, same starting point. But at age 30 they (or their physician) take it seriously. Lifestyle modification, plus pharmacotherapy if needed, brings the sustained systolic down to the 120 reference. By age 45 their cumulative excess is 10 × 14 (ages 20 to 30) + 15 × 0 (ages 30 to 45) = 140 excess mmHg-years. By age 65, still 140. The meter stopped running the day the pressure came back to baseline. Relative to Case A, they have avoided 490 excess mmHg-years of accumulated wall stress by the time they reach 65.

Case C. Same 35-year-old. Acts now, at 35, instead of at 30. Cumulative excess by 45 is 15 × 14 + 10 × 0 = 210 excess mmHg-years. By 65, still 210. The five-year delay between Cases B and C costs about 70 excess mmHg-years locked in for life, and the avoided savings compound with every additional decade above baseline that gets avoided.

These numbers are illustrative, not prescriptive. Real lifetime blood pressure doesn’t sit flat at any value. It drifts up with age, varies with stress, weight, sleep, training, sodium intake, and everything else in a life. The choice of 120 as the reference is the public-facing threshold; pick 115 instead and every number above gets larger. Hazard ratios on cumulative-exposure terms vary across studies and populations. But the direction is right, the magnitudes are plausible, and the lesson is the same as it was for cholesterol: the timeline of your pressure is not a backdrop to your risk. It’s the primary driver, once you’re above the line.

The math your physician probably hasn’t done with you is this. At thirty-five, a low-grade hypertensive reading isn’t a holding pattern. It’s an unfolding excess, with a meter that’s been running since adolescence.

The 35-year window

Most cardiology risk calculators, including the new PREVENT score the 2025 guideline now uses, estimate event probability over the next ten years. That is a clinically useful number for some decisions and a deeply misleading number for others.

A thirty-five-year-old’s ten-year PREVENT score will almost always come back low, because the next ten years, from 35 to 45, genuinely don’t carry a lot of absolute event risk for most people. The score isn’t broken. It is doing exactly what it was designed to do. But the next thirty years, the years where Lewington and CARDIA both say the most damage compounds, are not on the score’s clock.

The right question for a thirty-five-year-old isn’t “what’s my ten-year risk?” It’s “what’s my thirty-year cumulative exposure trajectory, and what is the leverage of intervening now versus in fifteen years?” SPRINT and the cumulative-exposure literature both say the answer to that second question is: substantial.

This is the leverage window. It is also the window where most people with low-grade hypertensive readings do nothing, because the calculator tells them they don’t need to. The 2025 AHA/ACC guideline is the first major U.S. document to push noticeably in the other direction, by making medication a recommendation for stage-1 patients whose pressure remains elevated after a serious lifestyle attempt, even at low ten-year predicted risk. The framework is finally catching up to the cumulative reality.

The artery wall is alive, and we’ll come back to that

A note on what “wall stress” actually means at the cellular level, because the math here can sound abstract.

The inner lining of every artery is a single layer of cells called the endothelium. It is not a passive surface. It senses pressure, flow, and chemical signals continuously, and it regulates a long list of vascular processes: tone, permeability, clotting, immune-cell adhesion, and the production of a key signaling molecule called nitric oxide. When that endothelial layer is exposed to higher mechanical stress over years, its signaling biology starts to change. The protective phenotype that keeps the vessel wall calm and non-adhesive begins to erode. And those changes happen most readily in places where the geometry of the artery creates disturbed local flow patterns, particularly at the branch points where one vessel splits into two.

A single coronary artery viewed laterally, branching into two daughter vessels at a Y-shaped bifurcation; cool blue-white streamlines flow orderly in the main trunk, then break into warm amber swirling vortices at the branch point with a subtle amber halo glow at the disturbance zone

The places where flow becomes complicated are the same places where atherosclerosis tends to start.

That biology is the through-line that connects borderline blood pressure to borderline cholesterol to subclinical inflammation to early plaque formation. It is the engine of everything the cardiac story will turn toward over the next several posts. I’m not going to deep-dive it here. Two reasons. First, this post is about the cumulative-exposure math, and I want the math to land cleanly on its own. Second, this is the kind of biology that deserves its own chapter, with the mechanism walked through carefully rather than waved at. That chapter is coming.

What you need to know for now is the through-line: the wall is alive, the pressure is doing real work on it every minute of every year, and the running total of that work is what eventually shows up on a CT angiogram.

What I’m telling people in their thirties and forties

Three things, in practical terms.

Measure with a home cuff, not just at the office. A single office reading is a sample size of one, taken under conditions that systematically bias the result, often upward (white coat) and sometimes downward (the rare patient whose office reading is lower than their lived reality). A validated upper-arm cuff, used at home over a few weeks, with proper technique (seated, back supported, feet flat, arm at heart level, measured after several minutes of quiet rest, two readings a minute apart, twice a day for a week), is the standard of evidence the 2025 AHA/ACC guideline now formally endorses for diagnostic confirmation.3 A home average is what you should be tracking, not a clinic snapshot.

One honest caveat about the cuff. The pressure a brachial cuff measures is peripheral pressure, the pressure in the arteries of your upper arm. The pressure that actually matters to your heart, brain, and kidneys is central pressure, the pressure at the aortic root and the large arteries near the heart. Those two numbers aren’t always the same. In young, healthy arteries they track closely. With age, arterial stiffening, and certain medication classes, peripheral and central pressures can diverge noticeably. Non-invasive devices that estimate central pressure are starting to move into consumer territory. This is a topic I’ll come back to in a future post, because for some of the people reading this, particularly anyone in their 50s and beyond, or anyone whose home cuff readings feel inconsistent with how they actually feel, central pressure is the next layer of resolution worth knowing about.

Reframe the conversation from “is my reading borderline?” to “what’s my mmHg-years trajectory?” The first question gets a snapshot answer. The second one forces a conversation about time. If you walk into a primary-care visit at 35 and ask, “what’s my cumulative blood-pressure exposure look like over the next twenty years if we don’t change anything?”, you’ve moved the dialogue from one inflection point to a curve. Even a physician who’s never thought in mmHg-years has to engage with you on that curve.

If your reading has been in the low 130s or upper 80s for a decade already, that’s not a snapshot. That’s data. Bring the time series to the appointment. Ten readings of 132/85 over fifteen years is not “borderline.” It is a confirmed cumulative-exposure pattern. Your physician’s instinct will be to look at the most recent point. The instinct that serves you, as I wrote earlier in this series when I had to fight for the right cardiac scan, is to show them the full picture and ask for what the full picture actually warrants.

When I look at my own labs from age 30 to 43, the mmHg-years arithmetic explains the timeline almost perfectly. The conversations I had at thirty would have been the cheapest cardiovascular intervention I could ever have made. None of them happened, because nothing in the framework gave anyone, including me, a reason to think they were urgent.

If your reading is in stage 1, here’s what to do this week

Future posts in this series will go deep on specific things that actually move cumulative blood pressure, both lifestyle moves with real evidence behind them and the medication conversation when it warrants. For now, the foundations. None of this is a substitute for the conversation with your own physician; the entries below are the conversation starters most worth raising at your next visit.

  • Talk to your doctor about a confirmed home-cuff average. This is exactly the conversation the 2025 guideline tells your primary care physician they should be having with you. If they aren’t, bring the time series. Ten readings a week, taken correctly, for a month is enough to land an honest baseline.
  • If you smoke, this is the single highest-leverage change you can make on the cardiovascular risk picture. Nothing else is close. The cumulative-exposure math on cigarettes is identical in structure to what we just walked through for blood pressure. Pack-years compound the same way mmHg-years do, and quitting moves the curve faster than any other single lever.
  • If you don’t have a structured exercise routine, start one. It doesn’t need to be elaborate. Most-days brisk walking with a couple of structured strength sessions per week moves both blood pressure and a long list of downstream variables. The post on cardiovascular training next week goes deeper on what the literature actually supports for adults adapting their training as they age.
  • If you snore loudly, gasp awake, or wake up unrefreshed, ask about obstructive sleep apnea. Untreated OSA pushes blood pressure up overnight and through the morning, and a meaningful percentage of “treatment-resistant” hypertension is undiagnosed OSA. Sleep apnea deserves its own future post; for now, the screen is a conversation away.
  • If you are carrying excess weight, particularly around the midsection, weight loss reliably moves the blood pressure number, particularly when paired with the other lifestyle changes above. Five to ten percent of body weight lost is roughly the threshold where the BP response usually becomes measurable on a home cuff. Another future post.

The foundation conversation your physician should be having with anyone in the stage-1 range is more productive when you walk in with the home-cuff data and the cumulative-exposure framing already in your head.

What’s next, and where we’re heading

The cumulative-exposure framework I just walked through for LDL and now for blood pressure isn’t a coincidence. It’s the same idea applied to two different inputs. Both add up over decades. Both do most of their damage between snapshots. Both are largely modifiable above a sensible reference.

Next week I want to step away from the lab values and toward the way I was training my body for thirty years, because that’s the next crack in the list I named a few weeks ago and it deserves its own evidence-deep treatment. I trained for the mirror. I didn’t train for the running total. The literature on what aging-adapted cardiovascular training actually looks like, and what I should have been doing instead of what I was doing, has gotten clearer in the last decade. That’s the chapter I want to walk through next.

One last thing before we go. Across the next several posts, you’ll start seeing me reach for a framework called the hallmarks of aging: the molecular and cellular processes that biologists now think drive aging itself. The framework was first laid out by Carlos López-Otín and colleagues in 2013 and substantially expanded in 2023 to twelve interlinked hallmarks. Things like genomic instability, cellular senescence, chronic inflammation, mitochondrial dysfunction, and altered intercellular communication, which is the bucket the nitric oxide story lives in.4 I’m going to start anchoring health concepts back to which hallmark or hallmarks they touch, because that is the lens through which I now think about every intervention. Borderline blood pressure isn’t just a cardiology story. In my reading, it intersects altered intercellular communication, chronic inflammation, mitochondrial dysfunction in the vessel wall, and a handful of others. We’ll trace those out as we get to each one.

More to come next week.

For more evidence-based analysis of the claims shaping your health decisions, visit calibratedsignal.com. Hard science, delivered honestly. No sponsors. No supplement deals. Just signal.

This post is educational, not medical advice. See Medical Disclaimer and Disclosures.

References

  1. The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116. PMID: 26551272

  2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913. PMID: 12493255

  3. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212-e316. PMID: 40811516

  4. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. PMID: 36599349

  5. Nwabuo CC, Appiah D, Moreira HT, et al. Long-term cumulative blood pressure in young adults and incident heart failure, coronary heart disease, stroke, and cardiovascular disease: The CARDIA study. Eur J Prev Cardiol. 2021;28(13):1445-1451. PMID: 34695218

  6. Reges O, Ning H, Wilkins JT, et al. Association of Cumulative Systolic Blood Pressure With Long-Term Risk of Cardiovascular Disease and Healthy Longevity: Findings From the Lifetime Risk Pooling Project Cohorts. Hypertension. 2021;77(2):347-356. PMID: 33342241

Nick Hanson, MS, RN, CEN
Mayo Clinic Board Certified Emergency Department RN
MS Bioinformatics & Computational Biology | University of Minnesota / Mayo Clinic
APRN-FNP Candidate | Duke University
PhD Candidate Bioinformatics & Computational Biology | University of Minnesota / Mayo Clinic
Published Epigenetics and Oncology Researcher
Former Health & Wellness Industry CEO (15+ years)
Certified Fitness Trainer (ISSA)